Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Pulmonary Drugs Market Size Shifted, And What Is the Outlook Through 2034?

In the past few years, the size of the pulmonary drugs market has seen consistent growth. The market’s growth is anticipated to rise from $54.28 billion in 2024 to $56.98 billion in 2025, with a compound annual growth rate (CAGR) of 5.0%. The historical growth is due to increasing rates of respiratory diseases, higher smoking rates, a growing elderly population, broader access to healthcare, and escalating pollution levels.

The market size of pulmonary drugs is predicted to experience robust expansion in the upcoming years. The market is projected to increase to $70.35 billion by 2029, with a compound annual growth rate (CAGR) of 5.4%. The growth during the projected period is attributed to factors such as the enhancement of healthcare infrastructures, increasing instances of cardiovascular diseases, expanding treatments at home, greater understanding of lung diseases, and a surge in asthma prevalence. Significant trends in the predicted period consist of advancements in technology, the use of AI for drug discovery, the adoption of smart inhalers, formulations based on nanotechnology, and progressions in gene therapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

What Are the Core Market Drivers Propelling Growth in the Pulmonary Drugs Industry?

The escalating incidence of respiratory conditions is anticipated to drive the growth of the pulmonary drugs market. Respiratory ailments are diseases that affect the lungs and airways, obstructing normal breathing and the exchange of oxygen. These conditions are becoming more prevalent due to the increasing rates of smoking, which causes lung damage and chronic illnesses. Pulmonary medications play a vital role in treating respiratory disorders by enhancing lung function, decreasing inflammation, and relieving airway blockage for improved breathing. For example, cited by the Bureau of Labor Statistics, a US government agency, in November 2023, the sickness rate among private-sector employers in 2022 surged to 45.2 cases per 10,000 Full-Time Equivalent (FTE) workers, a jump from 37.7 cases in 2021. This elevation is primarily attributed to a higher incidence of respiratory illnesses, which increased from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 in 2022. Hence, the expanding respiratory conditions are propelling the growth of the pulmonary drugs market.

How Is the Pulmonary Drugs Market Segmented?

The pulmonary drugs market covered in this report is segmented –

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

Which Regions Are Driving the Next Phase of the Pulmonary Drugs Market Growth?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Pulmonary Drugs Industry?

Leading firms in the pulmonary drugs market are increasingly focusing on developing innovative treatment methods like the single-inhaler triple therapy (SITT) to boost treatment effectiveness, promote patient compliance, and simplify medication regimens for improved disease control. SITT combines three separate medications into one inhaler to efficiently manage [chronic respiratory illnesses](https://www.wellmark.com/employer-news/chronic-respiratory-diseases-costly-conveniently-preventable) like chronic obstructive pulmonary disease (COPD). For instance, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, a pharmaceutical company based in India, introduced Trelegy Ellipta, marking India’s first SITT for patients struggling with COPD. This therapy merges fluticasone furoate, umeclidinium, and vilanterol, aiming to enhance lung efficiency and curb symptom exacerbations. The revolutionary Ellipta inhaler promises accurate dosing and promotes better patient compliance compared to therapies with multiple inhalers. This introduction aims to simplify treatment and enhance patient outcomes, considering the over 100 million COPD patients in India.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

How Is the Pulmonary Drugs Market Defined and What Are Its Core Parameters?

Pulmonary drugs refer to medications that target the respiratory system to improve lung function, reduce inflammation, and manage airway disorders. They are used for treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other respiratory illnesses.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23489

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model